E-resources
Peer reviewed
-
Nishikawa, Kazuhiro; Murotani, Kenta; Fujitani, Kazumasa; Inagaki, Hitoshi; Akamaru, Yusuke; Tokunaga, Shinya; Takagi, Masakazu; Tamura, Shigeyuki; Sugimoto, Naotoshi; Shigematsu, Tadashi; Yoshikawa, Takaki; Ishiguro, Tohru; Nakamura, Masato; Hasegawa, Hiroko; Morita, Satoshi; Miyashita, Yumi; Tsuburaya, Akira; Sakamoto, Junichi; Tsujinaka, Toshimasa
Cancer chemotherapy and pharmacology, 1/5, Volume: 83, Issue: 5Journal Article
Backgrounds Many patients with gastric cancer relapse during or early after adjuvant chemotherapy. The standard treatment for early relapse patients is a second-line chemotherapy (SLC) based on irinotecan, taxanes, or a platinum-based chemotherapy. The platinum-containing biweekly irinotecan plus cisplatin (IRI/CDDP) combination was assumed to be promising in several reports of clinical trials as SLC. TRICS trial, a randomized phase III study of IRI/CDDP vs. IRI in platinum-naïve gastric cancers refractory to S-1 monotherapy, revealed that both irinotecan-based chemotherapies were effective and well tolerated. Methods This study analyzed 108 patients in the TRICS trial who experienced early relapse. Patients receiving IRI/CDDP (IRI, 60 mg/m 2 ; CDDP, 30 mg/m 2 , q2w) versus IRI (150 mg/m 2 , q2w) were compared regarding overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety. Results The OS was 14.0 (95% confidence interval CI: 11.0–21.2) and 14.0 (95% CI: 10.7–16.5) months for IRI/CDDP and IRI, respectively (hazard ratio HR: 0.782; 95% CI: 0.515–1.188, P = 0.249). No significant differences were observed for PFS (5.0 vs. 4.5 months, respectively; HR: 0.802; 95% CI: 0.543–1.185, P = 0.268) or ORR (19.6% 95% CI: 9.4–33.9% vs. 23.3% 95% CI: 11.8–38.6%, respectively). The incidence of grade 3–4 anemia was higher for IRI/CDDP than for IRI (20% vs. 0%, respectively; P = 0.0006). Conclusion Our study showed no significant survival differences between IRI/CDDP and IRI in platinum-naïve patients who relapsed during or within 6 months after S-1 adjuvant therapy; therefore, IRI may be a good option in this population. Clinical trial information UMIN 000002571.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.